Adverse Drug Events at Emergency Department
NCT03442010 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13453
Last updated 2020-03-10
Summary
Emergency departments (EDs) are a crucial element of the health care systems at interface between hospital and communities. The goals of the ED are to make an initial diagnosis and deliver urgent and critical care 24 hour per day and 365 days a year. Also, many Adverse Drug Events (ADEs) are not identified by emergency physicians. ADEs are injuries resulting from a drug related medical intervention. Their detection, documentation and reporting are essential for adequate medical care and knowledge of risk/benefit profiles of medication throughout their lifecycle. However, a number of studies indicate that in clinical practice the under-reporting of ADEs is a pervasive and widespread problem. The main reasons for under-reporting were difficulty in determining the cause of the ADE, lack of time, poor integration of ADE-reporting systems and uncertainty about reporting procedures. Successful treatment of ADEs depends on the ability of physicians to attribute ADEs to a medication. Some studies have reported that pharmacists but also student pharmacists were one of the best health care providers to establish medication history. Consequently, the aims of our study were to assess prevalence and characteristics of ADEs identified in an emergency department and to identify factors associated with ADEs in ED patients.
This prospective observational study is conducted at the ED of a tertiary care hospital (University hospital of Montpellier). This department supports 80 000 patients every years. Patient were not included if they were less than 18 years old, present acute psychological disturbance or they did not agree to participate at this study.
For each patient included, a pharmaceutical team conducted: medication reconciliation process to establish medication history and a structured interviews to determine self-reported adherence and self-medication. ADEs were attributed to a medication by the treating senior emergency physician: directly during patient consultation or after being alerted by the pharmaceutical team.
Conditions
- Adverse Drug Event
Interventions
- OTHER
-
Detection of adverse drug events
Detection of adverse drug events
Sponsors & Collaborators
-
University Hospital, Montpellier
lead OTHER
Principal Investigators
-
Cyril BREUKER · University Hospital, Montpellier
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-11-01
- Primary Completion
- 2019-12-01
- Completion
- 2019-12-01
Countries
- France
Study Locations
More Related Trials
-
Medication Reconciliation in an Emergency Department: How to Prioritize Patients ?
NCT03955965 ·Status: COMPLETED
-
The Incidence, Clinical Characteristics and Outcome of Infective Endocarditis Among Intravenous Drug Abusers Versus Non-Drug Abusers.
NCT06194409 ·Status: RECRUITING
-
Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose
NCT05809271 ·Status: COMPLETED ·Phase: PHASE1
-
Voluntary Drug Poisoning by Psychoactive Molecules: Identify Cognitive Markers
NCT03481192 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of the Management of Tramadol Use Disorders
NCT04550754 ·Status: COMPLETED
-
Identification of Psychoactive Substance Users in Young Adults (16 to 25 Years Old) Visiting the Emergency Department
NCT04173546 ·Status: COMPLETED
-
Low Dose Ketamine Intra Nasal Traumatology
NCT03233035 ·Status: COMPLETED ·Phase: PHASE2
-
Epidemiology of Acute Self-poisoning in Emergency Services in France
NCT02518386 ·Status: COMPLETED
-
Quantification of Drugs and Their Degradation Products
NCT01828372 ·Status: UNKNOWN ·Phase: NA
-
Drug Interactions With Risk of QT-prolongation in a General Hospital
NCT02043912 ·Status: COMPLETED
-
Outcomes of Antipsychotic Medication Used in the Emergency Department
NCT02504450 ·Status: COMPLETED
-
Haloperidol Prophylaxis in Older Emergency Department Patients
NCT01530308 ·Status: COMPLETED ·Phase: PHASE4
-
The Discriminative Effects of Tramadol in Humans
NCT00499746 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Quantitative Xylazine Measurement in ED
NCT06949605 ·Status: COMPLETED
-
Psychiatric Disorders in Addiction - Interest of Screening and Influence on Relapse
NCT07023419 ·Status: RECRUITING
-
The Norwegian Addiction, Pain and Trauma Study
NCT04908410 ·Status: ACTIVE_NOT_RECRUITING
-
Differential Acute Tolerance Development to Effects of Nitrous Oxide - 7
NCT00000255 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
NCT02144415 ·Status: COMPLETED ·Phase: PHASE1
-
Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment
NCT04343339 ·Status: COMPLETED
-
Trends of Acute Intoxication in Poison Control Centre
NCT05098418 ·Status: UNKNOWN
-
Cardiovascular Safety After Continuous Ketamine Infusion
NCT03979105 ·Status: COMPLETED
-
Systemic Ketamine for the Improvement of Post-Operative Analgesia at the Alcohol-Dependent Patient
NCT00329394 ·Status: SUSPENDED ·Phase: PHASE3
-
The NeXT Study; The Netherlands XTC Toxicity Study
NCT00235768 ·Status: COMPLETED
-
Medical Students and Psychoactive Substances Use
NCT04209101 ·Status: COMPLETED
-
Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls
NCT04648137 ·Status: COMPLETED ·Phase: NA